- Home
- ITIC vs SLRX Comparison
ITIC vs SLRX Comparison
Compare ITIC & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- SLRX
- Stock Information
- Founded
- ITIC 1972
- SLRX N/A
- Country
- ITIC United States
- SLRX United States
- Employees
- ITIC N/A
- SLRX N/A
- Industry
- ITIC Specialty Insurers
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- SLRX Health Care
- Exchange
- ITIC Nasdaq
- SLRX Nasdaq
- Market Cap
- ITIC 440.1M
- SLRX 1.8M
- IPO Year
- ITIC N/A
- SLRX N/A
- Fundamental
- Price
- ITIC $215.93
- SLRX $0.90
- Analyst Decision
- ITIC
- SLRX
- Analyst Count
- ITIC 0
- SLRX 0
- Target Price
- ITIC N/A
- SLRX N/A
- AVG Volume (30 Days)
- ITIC 62.4K
- SLRX 3.5M
- Earning Date
- ITIC 08-05-2025
- SLRX 08-08-2025
- Dividend Yield
- ITIC 7.43%
- SLRX N/A
- EPS Growth
- ITIC 18.56
- SLRX N/A
- EPS
- ITIC 15.69
- SLRX N/A
- Revenue
- ITIC $261,197,999.00
- SLRX N/A
- Revenue This Year
- ITIC N/A
- SLRX N/A
- Revenue Next Year
- ITIC N/A
- SLRX N/A
- P/E Ratio
- ITIC $13.73
- SLRX N/A
- Revenue Growth
- ITIC 15.27
- SLRX N/A
- 52 Week Low
- ITIC $174.85
- SLRX $0.45
- 52 Week High
- ITIC $290.40
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- ITIC 52.87
- SLRX 50.55
- Support Level
- ITIC $210.27
- SLRX $0.86
- Resistance Level
- ITIC $218.93
- SLRX $1.33
- Average True Range (ATR)
- ITIC 5.82
- SLRX 0.15
- MACD
- ITIC 2.50
- SLRX -0.01
- Stochastic Oscillator
- ITIC 85.37
- SLRX 40.19
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.